WASHINGTON (dpa-AFX) - Intersect ENT Inc., a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, announced the pricing of its initial public offering of 5 million shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Intersect ENT.
The shares are expected to begin trading on The Nasdaq Global Market under the ticker symbol 'XENT' on July 24, 2014.
In addition, Intersect ENT has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Intersect ENT at the initial public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about July 29, 2014, subject to customary closing conditions.
Copyright RTT News/dpa-AFX